Roche Acquires Carmot Therapeutics for $2.7 Billion

Roche Acquires Carmot Therapeutics for $2.7 Billion

Carmot Therapeutics Inc. announced on December 4 that it entered into a definitive merger agreement to be acquired by Roche Holding AG at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone payments.  Carmot Therapeutics is a biotechnology firm with injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug in clinical development. The biotechnology company filed to go public in November 2023.  Roche Holding AG, commonly known as Roche, operates in the pharmaceuticals and diagnostics businesses worldwide. The company’s headquarters are located in Basel, Switzerland. According to its 2022 annual report, Roche’s net sales... Read More »
Healthpeak Properties and Physicians Realty Trust Announce $21 Billion Merger

Healthpeak Properties and Physicians Realty Trust Announce $21 Billion Merger

Healthpeak Properties and Physicians Realty Trust announced on October 30 that they have entered into a definitive agreement to combine in an all-stock merger of equals valued at approximately $21 billion.  According to data captured in the LevinPro HC database, this transaction marks the second largest healthcare transaction of 2023 by purchase price, behind Pfizer’s $43 billion acquisition of Seagen Inc. announced in March.  Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. According to its 2022 financial... Read More »
Pfizer Acquires Seagen for $43 Billion

Pfizer Acquires Seagen for $43 Billion

Pfizer Inc. has acquired Seagen Inc. for $43 billion, representing the largest purchase price for a biotechnology deal in 2023. The transaction is expected to be completed in late 2023 or early 2024. Pfizer will pay $229 in cash for each share of Seagen and pay primarily through $31 billion in new, long-term debt. Shares of Pfizer rose 2% to $40.26 after markets opened on March 13 while Seagen’s stock soared more than 15% to nearly $200. Seagen Inc. specializes in working with antibody-drug conjugate technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding tissue. It also has a... Read More »
A Good Start for Biotech in 2020

A Good Start for Biotech in 2020

Early in January 2019, Bristol-Myers Squibb’s (NYSE: BMY) $74 billion acquisition of Celgene Corporation dominated the headlines. But despite that big deal, 2019 was a rather lackluster year for the Biotechnology sector. However, the opening quarter of 2020 is showing some promise. This year’s J.P. Morgan Healthcare Conference came and went without any major announcements, but the Biotech sector is seeing a steady start, with a modest $930 million in spending with 11 announced transactions. A bulk of that dollar volume came from Incyte Corporation’s (NASDAQ: INCY) deal with MorphoSys AG (NASDAQ: MOR) for tafasitamab. The collaboration and license agreement aim to further... Read More »
Array BioPharma Grabbed By Pfizer for $11.4 Billion

Array BioPharma Grabbed By Pfizer for $11.4 Billion

With AbbVie Inc.’s  (NYSE: ABBV) surprise $87 billion bid for Allergan plc (NYSE: AGN) dominating headlines this week, you’d be forgiven for forgetting Pfizer (NYSE: PFE) just bought Array BioPharma (NASDAQ: ARRY) for $11.4 billion only days before. It’s the pharmaceutical giant’s biggest deal of the year thus far in announced dollar volume, and only second behind the aforementioned transaction. The terms included $48 per share in cash, with 237,500,000 shares outstanding, representing a 62% premium to ARRY’s closing price on Friday, June 13. Array BioPharma is a commercial-stage biopharmaceutical company focused on the discovery, development, and... Read More »